Dyne Therapeutics, Inc. DYN
Institutional shares held
122 Million
36.5K
calls
74.3K
puts
Total value of holdings
$1.57B
$469K
calls
$955K
puts
Market Cap
$666M
51,765,400
Shares Out.
Institutional ownership
235.6%
# of Institutions
211
We take great care to ensure that the data presented and summarized in this overview for Dyne Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding DYN
View all-
Ra Capital Management, L.P. Boston, MA9.71MShares$125 Million2.02% of portfolio
-
Janus Henderson Group PLC London, X09.44MShares$121 Million0.05% of portfolio
-
Atlas Venture Life Science Advisors, LLC9.13MShares$117 Million19.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.65MShares$98.4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$95 Million0.01% of portfolio
-
Fcpm Iii Services B.V. Naarden, P75.46MShares$70.3 Million14.09% of portfolio
-
Siren, L.L.C. New York, NY4.84MShares$62.2 Million2.38% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA3.77MShares$48.4 Million7.31% of portfolio
-
State Street Corp Boston, MA3.36MShares$43.2 Million0.0% of portfolio
-
Braidwell LP Stamford, CT3.27MShares$42.1 Million1.91% of portfolio
Latest Institutional Activity in DYN
Top Purchases
Top Sells
About DYN
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Insider Transactions at DYN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 05
2025
|
John Cox CEO & President |
SELL
Open market or private sale
|
Direct |
2,640
-1.31%
|
$34,320
$13.41 P/Share
|
|
Sep 05
2025
|
Johanna Friedl Naderer Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
144
-0.15%
|
$1,872
$13.41 P/Share
|
|
Sep 05
2025
|
Douglas Kerr Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
873
-0.98%
|
$11,349
$13.41 P/Share
|
|
Sep 04
2025
|
Johanna Friedl Naderer Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
894
-0.93%
|
$11,622
$13.27 P/Share
|
|
Sep 04
2025
|
Douglas Kerr Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,552
-3.83%
|
$46,176
$13.27 P/Share
|
|
Jul 15
2025
|
John Cox CEO & President |
SELL
Bona fide gift
|
Direct |
40,000
-4.41%
|
-
|
|
Jul 14
2025
|
John Cox CEO & President |
BUY
Open market or private purchase
|
Direct |
100,000
+29.22%
|
$900,000
$9.11 P/Share
|
|
Jun 05
2025
|
Douglas Kerr Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,342
-1.43%
|
$17,446
$13.35 P/Share
|
|
Jun 05
2025
|
John Cox CEO & President |
SELL
Open market or private sale
|
Direct |
4,060
-2.78%
|
$52,780
$13.35 P/Share
|
|
Jun 05
2025
|
Johanna Friedl Naderer Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
146
-0.15%
|
$1,898
$13.35 P/Share
|
|
Mar 31
2025
|
Erick Lucera Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
66,100
+50.0%
|
-
|
|
Mar 13
2025
|
Johanna Friedl Naderer Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
143
-0.15%
|
$1,716
$12.12 P/Share
|
|
Mar 11
2025
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,153
-1.09%
|
$23,683
$11.38 P/Share
|
|
Mar 11
2025
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
1,343
-1.09%
|
$14,773
$11.38 P/Share
|
|
Mar 05
2025
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
917
-0.74%
|
$10,087
$11.83 P/Share
|
|
Mar 05
2025
|
John Cox CEO & President |
SELL
Open market or private sale
|
Direct |
4,061
-2.7%
|
$44,671
$11.83 P/Share
|
|
Mar 05
2025
|
Douglas Kerr Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,343
-1.41%
|
$14,773
$11.83 P/Share
|
|
Mar 05
2025
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,094
-0.55%
|
$12,034
$11.83 P/Share
|
|
Feb 18
2025
|
Oxana Beskrovnaya Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
2,598
-1.29%
|
$33,774
$13.95 P/Share
|
|
Feb 18
2025
|
Richard William Scalzo SVP, Head of Finance & Admin. |
SELL
Open market or private sale
|
Direct |
2,488
-1.96%
|
$32,344
$13.95 P/Share
|
Last 12 Months Summary
Buy / Acquisition
1.62M
Shares
From
9
Insiders
| Grant, award, or other acquisition | 1.51M shares |
|---|---|
| Open market or private purchase | 100K shares |
| Exercise of conversion of derivative security | 16.5K shares |
Sell / Disposition
840K
Shares
From
10
Insiders
| Open market or private sale | 800K shares |
|---|---|
| Bona fide gift | 40K shares |